Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

NCT03245151 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent and Refractory Solid Tumors

Interventions

DRUG: Lenvatinib
DRUG: Everolimus

Sponsor

Eisai Inc.

Collaborators

[object Object]